vs
STANDARD BIOTOOLS INC.（LAB）与null（SGRP）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是STANDARD BIOTOOLS INC.的1.1倍（$22.0M vs $19.6M），null净利率更高（-74.1% vs -177.4%，领先103.3%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -33.4%），null自由现金流更多（$-3.9M vs $-23.1M），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -33.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
SPAR是源自荷兰的跨国零售加盟品牌，1932年由阿德里安·范·威尔创立，最初名为DESPAR。该集团为独立所有及运营的食品零售店提供品牌授权、供货与运营支持服务，目前门店数量最多的市场为英国。
LAB vs SGRP — 直观对比
营收规模更大
SGRP
是对方的1.1倍
$19.6M
营收增速更快
LAB
高出21.9%
-33.4%
净利率更高
SGRP
高出103.3%
-177.4%
自由现金流更多
SGRP
多$19.2M
$-23.1M
两年增速更快
LAB
近两年复合增速
-33.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $22.0M |
| 净利润 | $-34.7M | $-16.3M |
| 毛利率 | 48.5% | -10.6% |
| 营业利润率 | -168.5% | -57.8% |
| 净利率 | -177.4% | -74.1% |
| 营收同比 | -11.5% | -33.4% |
| 净利润同比 | -28.8% | -186.2% |
| 每股收益（稀释后） | $-0.09 | $-0.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSGRP
| Q4 25 | — | $22.0M | ||
| Q3 25 | $19.6M | $41.4M | ||
| Q2 25 | $21.8M | $38.6M | ||
| Q1 25 | $40.8M | $34.0M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | $22.1M | $37.8M | ||
| Q2 24 | $22.5M | $43.4M | ||
| Q1 24 | $45.5M | $49.4M |
净利润LABSGRP
| Q4 25 | — | $-16.3M | ||
| Q3 25 | $-34.7M | $-8.8M | ||
| Q2 25 | $-33.5M | $-1.0K | ||
| Q1 25 | $-26.0M | $462.0K | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | $-26.9M | $-182.0K | ||
| Q2 24 | $-45.7M | $-3.9M | ||
| Q1 24 | $-32.2M | $6.6M |
毛利率LABSGRP
| Q4 25 | — | -10.6% | ||
| Q3 25 | 48.5% | 18.6% | ||
| Q2 25 | 48.8% | 23.5% | ||
| Q1 25 | 48.4% | 21.4% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | 54.9% | 22.3% | ||
| Q2 24 | 46.1% | 20.7% | ||
| Q1 24 | 53.1% | 19.7% |
营业利润率LABSGRP
| Q4 25 | — | -57.8% | ||
| Q3 25 | -168.5% | -14.3% | ||
| Q2 25 | -118.1% | 1.9% | ||
| Q1 25 | -80.8% | 3.0% | ||
| Q4 24 | — | -16.6% | ||
| Q3 24 | -120.9% | -4.0% | ||
| Q2 24 | -134.5% | -2.2% | ||
| Q1 24 | -132.2% | 17.6% |
净利率LABSGRP
| Q4 25 | — | -74.1% | ||
| Q3 25 | -177.4% | -21.2% | ||
| Q2 25 | -153.7% | -0.0% | ||
| Q1 25 | -63.8% | 1.4% | ||
| Q4 24 | — | -17.3% | ||
| Q3 24 | -122.0% | -0.5% | ||
| Q2 24 | -203.3% | -9.0% | ||
| Q1 24 | -70.6% | 13.4% |
每股收益（稀释后）LABSGRP
| Q4 25 | — | $-0.69 | ||
| Q3 25 | $-0.09 | $-0.37 | ||
| Q2 25 | $-0.09 | $0.00 | ||
| Q1 25 | $-0.07 | $0.02 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | $-0.07 | $-0.01 | ||
| Q2 24 | $-0.12 | $-0.16 | ||
| Q1 24 | $-0.27 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $3.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $622.0K |
| 总资产 | $539.6M | $44.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSGRP
| Q4 25 | — | $3.3M | ||
| Q3 25 | $129.4M | $8.2M | ||
| Q2 25 | $158.6M | $13.9M | ||
| Q1 25 | $150.9M | $17.9M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $210.6M | $19.7M | ||
| Q2 24 | $269.8M | $21.7M | ||
| Q1 24 | $287.1M | $16.6M |
总债务LABSGRP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSGRP
| Q4 25 | — | $622.0K | ||
| Q3 25 | $399.7M | $16.6M | ||
| Q2 25 | $424.5M | $24.9M | ||
| Q1 25 | $454.6M | $24.7M | ||
| Q4 24 | — | $24.3M | ||
| Q3 24 | $489.3M | $29.3M | ||
| Q2 24 | $510.3M | $29.4M | ||
| Q1 24 | $577.3M | $33.0M |
总资产LABSGRP
| Q4 25 | — | $44.1M | ||
| Q3 25 | $539.6M | $61.7M | ||
| Q2 25 | $557.0M | $71.6M | ||
| Q1 25 | $579.6M | $70.2M | ||
| Q4 24 | — | $56.4M | ||
| Q3 24 | $681.5M | $67.4M | ||
| Q2 24 | $708.7M | $70.0M | ||
| Q1 24 | $777.7M | $104.5M |
负债/权益比LABSGRP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-3.9M |
| 自由现金流率自由现金流/营收 | -118.1% | -17.8% |
| 资本支出强度资本支出/营收 | 4.5% | 6.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-21.4M |
8季度趋势，按日历期对齐
经营现金流LABSGRP
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $-22.2M | $-4.1M | ||
| Q2 25 | $-20.7M | $-7.9M | ||
| Q1 25 | $-30.3M | $-4.0M | ||
| Q4 24 | — | $65.0K | ||
| Q3 24 | $-27.9M | $-900.0K | ||
| Q2 24 | $-39.0M | $-445.0K | ||
| Q1 24 | $-62.5M | $615.0K |
自由现金流LABSGRP
| Q4 25 | — | $-3.9M | ||
| Q3 25 | $-23.1M | $-4.6M | ||
| Q2 25 | $-22.6M | $-8.3M | ||
| Q1 25 | $-35.3M | $-4.6M | ||
| Q4 24 | — | $-166.0K | ||
| Q3 24 | $-30.1M | $-1.0M | ||
| Q2 24 | $-41.0M | $-785.0K | ||
| Q1 24 | $-63.3M | $184.0K |
自由现金流率LABSGRP
| Q4 25 | — | -17.8% | ||
| Q3 25 | -118.1% | -11.2% | ||
| Q2 25 | -103.6% | -21.5% | ||
| Q1 25 | -86.6% | -13.4% | ||
| Q4 24 | — | -0.5% | ||
| Q3 24 | -136.4% | -2.7% | ||
| Q2 24 | -182.2% | -1.8% | ||
| Q1 24 | -138.9% | 0.4% |
资本支出强度LABSGRP
| Q4 25 | — | 6.6% | ||
| Q3 25 | 4.5% | 1.4% | ||
| Q2 25 | 8.7% | 1.1% | ||
| Q1 25 | 12.4% | 1.5% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | 10.2% | 0.3% | ||
| Q2 24 | 8.6% | 0.8% | ||
| Q1 24 | 1.7% | 0.9% |
现金转化率LABSGRP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SGRP
暂无分部数据
